Konference: 2006 31st Congress ESMO - účast ČR
Kategorie: Podpůrná onkologická léčba, výživa nemocných a ošetřovatelská péče
Téma: Supportive care
Číslo abstraktu: 1008P
Autoři: MUDr. Jiří Salvét; Doc. MUDr. Luboš Holubec (jr.), Ph.D., MBA; prof. MUDr. Jindřich Fínek, Ph.D.; Prof. MUDr. Ondřej Topolčan, CSc.
Aim of the study: The aim of this study was to assess the
changes of cardio-specific enzymes in patients treated with
radiotherapy and chemotherapy and also to evaluate the incidence
rate of the pathological values of the thyroid function markers in
cancer patients treated by 5 fluorouracil (5-FU) regimen
Materials and Methods: Cardio-specific enzymes were assessed in a total of 37 patients treated with radiotherapy (group I) and in a total of 42 colorectal cancer patients treated with 4 cycles of adjuvant or palliative chemotherapy with 5-FU regimen (group II). In 30 patients of the group of colorectal cancer patients we also evaluated the markers of thyroid function (group III). The following markers were assessed: cardio-specific enzymes (BNP, NT- pro BNP, Troponin I, Seristra) and markers of thyroid function (TSH, fT4, anti TPO).
Results: In group I 30% of patients (11/37), after completion of radiotherapy, had pathological values of BNP (above 100 pg/L) suggestive of cardiovascular disease. In group II we confirmed an increase in serum levels of BNP and Troponin I with a high incidence rate. In group III we confirmed hypothyroidism in 15% of patients (3/20) and hyperthyroidism also in 15% of cases (3/20).
Conclusions: Based on our results we can conclude that is very important to monitor the side effect of anti- cancer therapy using laboratory methods. It is very important in a situation where conventional imaging methods are not available or their prompt interpretation is missing.
This study was supported by the grant of League against the cancer, Czech Rep. and by the grant VZ MSM 0021620819.
Materials and Methods: Cardio-specific enzymes were assessed in a total of 37 patients treated with radiotherapy (group I) and in a total of 42 colorectal cancer patients treated with 4 cycles of adjuvant or palliative chemotherapy with 5-FU regimen (group II). In 30 patients of the group of colorectal cancer patients we also evaluated the markers of thyroid function (group III). The following markers were assessed: cardio-specific enzymes (BNP, NT- pro BNP, Troponin I, Seristra) and markers of thyroid function (TSH, fT4, anti TPO).
Results: In group I 30% of patients (11/37), after completion of radiotherapy, had pathological values of BNP (above 100 pg/L) suggestive of cardiovascular disease. In group II we confirmed an increase in serum levels of BNP and Troponin I with a high incidence rate. In group III we confirmed hypothyroidism in 15% of patients (3/20) and hyperthyroidism also in 15% of cases (3/20).
Conclusions: Based on our results we can conclude that is very important to monitor the side effect of anti- cancer therapy using laboratory methods. It is very important in a situation where conventional imaging methods are not available or their prompt interpretation is missing.
This study was supported by the grant of League against the cancer, Czech Rep. and by the grant VZ MSM 0021620819.
Datum přednesení příspěvku: 29. 6. 2006
